Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials (Unbekannt)
- Neue Suche nach: Di Federico, Alessandro
- Neue Suche nach: Rizzo, Alessandro
- Neue Suche nach: Carloni, Riccardo
- Neue Suche nach: De Giglio, Andrea
- Neue Suche nach: Bruno, Riccardo
- Neue Suche nach: Ricci, Dalia
- Neue Suche nach: Brandi, Giovanni
- Neue Suche nach: Di Federico, Alessandro
- Neue Suche nach: Rizzo, Alessandro
- Neue Suche nach: Carloni, Riccardo
- Neue Suche nach: De Giglio, Andrea
- Neue Suche nach: Bruno, Riccardo
- Neue Suche nach: Ricci, Dalia
- Neue Suche nach: Brandi, Giovanni
In:
Expert Opinion on Investigational Drugs
;
31
, 4
;
361-369
;
2022
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
-
Beteiligte:Di Federico, Alessandro ( Autor:in ) / Rizzo, Alessandro ( Autor:in ) / Carloni, Riccardo ( Autor:in ) / De Giglio, Andrea ( Autor:in ) / Bruno, Riccardo ( Autor:in ) / Ricci, Dalia ( Autor:in ) / Brandi, Giovanni ( Autor:in )
-
Erschienen in:Expert Opinion on Investigational Drugs ; 31, 4 ; 361-369
-
Verlag:
- Neue Suche nach: Taylor & Francis
-
Erscheinungsdatum:03.04.2022
-
Format / Umfang:9 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Unbekannt
-
Schlagwörter:
-
Datenquelle:
Inhaltsverzeichnis – Band 31, Ausgabe 4
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 331
-
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gapsRizzo, Alessandro / Palmiotti, Gennaro et al. | 2022
- 333
-
Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?Rizzo, Alessandro et al. | 2022
- 337
-
Camrelizumab: an investigational agent for hepatocellular carcinomaXu, Bin / Sun, Hui-Chuan et al. | 2022
- 347
-
Durvalumab: an investigational agent for unresectable hepatocellular carcinomaMaestri, Marta / Pallozzi, Maria / Santopaolo, Francesco / Cerrito, Lucia / Pompili, Maurizio / Gasbarrini, Antonio / Ponziani, Francesca Romana et al. | 2022
- 361
-
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trialsDi Federico, Alessandro / Rizzo, Alessandro / Carloni, Riccardo / De Giglio, Andrea / Bruno, Riccardo / Ricci, Dalia / Brandi, Giovanni et al. | 2022
- 371
-
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?Rizzo, Alessandro / Dadduzio, Vincenzo / Ricci, Angela Dalia / Massari, Francesco / Di Federico, Alessandro / Gadaleta-Caldarola, Gennaro / Brandi, Giovanni et al. | 2022
- 379
-
Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progressBrown, Zachary J. / Hewitt, D Brock / Pawlik, Timothy M et al. | 2022
- 393
-
FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potentialXie, Hao / Alem Glison, Diego M / Kim, Richard D. et al. | 2022
- 401
-
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trialsCammarota, Antonella / Zanuso, Valentina / D’Alessio, Antonio / Pressiani, Tiziana / Personeni, Nicola / Rimassa, Lorenza et al. | 2022
- 415
-
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?Rizzo, Alessandro / Ricci, Angela Dalia et al. | 2022
- 425
-
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trialsCammarota, Antonella / Zanuso, Valentina / D’Alessio, Antonio / Pressiani, Tiziana / Bozzarelli, Silvia / Personeni, Nicola / Rimassa, Lorenza et al. | 2022